Zacks Research Issues Positive Estimate for Novavax Earnings

Novavax, Inc. (NASDAQ:NVAX) – Research analysts at Zacks Research upped their FY2025 earnings per share estimates for shares of Novavax in a research note issued on Tuesday, January 28th. Zacks Research analyst S. Ganoria now forecasts that the biopharmaceutical company will earn ($0.72) per share for the year, up from their previous estimate of ($0.77). The consensus estimate for Novavax’s current full-year earnings is ($1.31) per share.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.07. The firm had revenue of $84.51 million during the quarter, compared to analyst estimates of $65.80 million. The business’s revenue was down 54.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.26) EPS.

Several other brokerages also recently issued reports on NVAX. HC Wainwright reaffirmed a “buy” rating and set a $19.00 price target on shares of Novavax in a report on Tuesday, December 10th. B. Riley restated a “buy” rating and set a $26.00 price objective (up previously from $23.00) on shares of Novavax in a report on Thursday, October 10th. Finally, Jefferies Financial Group dropped their price target on Novavax from $31.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, October 16th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $17.83.

Novavax Stock Down 3.6 %

Shares of NASDAQ NVAX opened at $8.69 on Friday. The business’s 50 day moving average price is $8.83 and its two-hundred day moving average price is $10.79. The company has a market cap of $1.39 billion, a PE ratio of -3.85 and a beta of 2.07. Novavax has a twelve month low of $3.53 and a twelve month high of $23.86.

Institutional Trading of Novavax

A number of hedge funds have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Novavax by 38.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 1,598 shares during the last quarter. Victory Capital Management Inc. boosted its stake in shares of Novavax by 12.0% during the third quarter. Victory Capital Management Inc. now owns 19,292 shares of the biopharmaceutical company’s stock valued at $244,000 after purchasing an additional 2,072 shares in the last quarter. Creative Planning grew its holdings in shares of Novavax by 12.5% during the second quarter. Creative Planning now owns 24,143 shares of the biopharmaceutical company’s stock worth $306,000 after purchasing an additional 2,692 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Novavax by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,965 shares of the biopharmaceutical company’s stock valued at $273,000 after buying an additional 3,174 shares during the last quarter. Finally, Spire Wealth Management acquired a new stake in Novavax during the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 53.04% of the company’s stock.

Insider Transactions at Novavax

In other Novavax news, Director Rachel K. King sold 4,150 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $9.02, for a total transaction of $37,433.00. Following the completion of the transaction, the director now owns 14,770 shares of the company’s stock, valued at approximately $133,225.40. The trade was a 21.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James F. Young sold 5,400 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total transaction of $43,200.00. Following the completion of the sale, the director now owns 51,760 shares in the company, valued at approximately $414,080. The trade was a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,150 shares of company stock valued at $119,641. 1.00% of the stock is owned by corporate insiders.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.